OpenAI, AI Drugs, & Siri's Fate (Ep. 545)
The September 5th episode of The Daily AI Show was a Friday wrap-up covering multiple AI stories. The hosts discussed OpenAI’s rumored LinkedIn competitor, Apple’s shift toward building its own AI-powered search for Siri, FDA approval of the first AI-designed drug for animal trials, industrial robotics, and other emerging AI developments.Key Points DiscussedOpenAI plans to launch a job platform in 2026, potentially disrupting LinkedIn with AI-powered talent matching and broader ambitions in browsers, social media, CRMs, and office suites.Apple is preparing to build its own AI search engine to replace Google as the default in Siri, partly due to new antitrust rulings. This comes as iPhone sales in India grow despite global challenges.The FDA approved the first AI-designed cancer drug for animal trials, developed in 18 months instead of the usual 42, marking a breakthrough in faster, cheaper drug discovery.Penn State researchers also developed an AI system using diffusion models to generate and refine peptide sequences, accelerating drug candidate selection.Industrial robotics remains dominated by Japan and Europe, with Kuka, ABB, and Fanuc leading sectors like automotive and electronics. The discussion tied in how embodied AI could follow the same trajectory.IBM and NASA created an AI model to predict large solar flares, helping protect against potential EMP-level disruptions to global infrastructure.Meta is advancing Llama 5 and using Anthropic’s Claude Code internally, while exploring integration of external models like Google and OpenAI into its apps.Discussion of Codex vs Claude Code highlighted rapid improvements in AI coding assistants, with expectations that Gemini 3 will intensify competition.Timestamps & Topics00:00:00 💡 Intro and topics preview00:03:07 🍏 Apple’s AI search plans and Siri updates00:07:10 📱 Apple’s India growth and iPhone pricing challenges00:09:21 📱 Frustrations with Apple Intelligence integration00:10:27 📱 Pixel 10 interest as an Apple alternative00:12:00 👻 Snapchat’s staying power with younger generations00:15:35 💊 FDA approval of AI-designed cancer drug for trials00:19:54 🧪 Penn State’s AI diffusion model for peptide design00:22:10 💉 Shortening the timeline for drug discovery and trials00:24:22 🏢 OpenAI’s LinkedIn competitor and broader platform ambitions00:26:30 🌐 OpenAI’s AI-powered web browser plans00:27:54 📣 OpenAI’s prototype social media platform00:28:23 📊 CRM proof of concept and Salesforce pressure00:29:44 📑 OpenAI’s push toward an office suite competitor00:30:13 💾 OpenAI and Broadcom’s $10B AI chip partnership00:31:52 💰 OpenAI’s valuation trajectory and trillion-dollar potential00:33:28 💸 Equity, stock options, and AI talent poaching00:36:41 🤖 Industrial robotics market breakdown (Japan, Germany, Switzerland, China)00:39:35 🎢 Kuka arms in automotive and theme park rides00:43:30 🌞 IBM and NASA’s AI solar flare prediction model00:45:09 🦙 Meta’s Llama 5, model integrations, and use of Claude Code00:47:20 💻 Codex vs Gemini 2.5 Pro in coding tasks00:48:13 📚 Notebook LM adoption and AI in education00:49:35 🗞️ Wrap up, newsletter, and community inviteThe Daily AI Show Co-Hosts: Andy Halliday, Beth Lyons, Brian Maucere, Eran Malloch, Jyunmi Hatcher, and Karl Yeh